As of Feb 27
| -0.03 / -1.35%|
The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +82.65% increase from the last price of 2.19.
The current consensus among 3 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.